OMDA Stock Forecast & Price Target

Omada Health is compelling because its B2B2C model sells through employers, health plans, and major PBMs, creating sticky recurring revenue with high retention, low customer acquisition costs, and multi-year contract visibility. The company’s scale opportunity is still early, with about 25 million covered lives, roughly 1.1 million enrolled members, more than 90% customer retention, and 33%+ of contracts now multi-product, while GLP-1-related billings have increased about 52% year over year and engagement among top clients can reach 25% to 30%. Fundamentally, management’s raised long-term targets for 80% gross margin and 30% EBITDA margin, alongside expected 20%+ revenue growth and a broader cardiometabolic platform, support the view that Omada can expand both earnings power and addressable market.

Omada Health is challenged by structural and commercial weaknesses that weigh on its long-term fundamentals, including HIPAA-related compliance burdens, a highly competitive virtual care market, and the need to continually prove measurable outcomes to preserve customer and channel confidence. Its business remains exposed to weak consumer engagement, concentration risk from affiliates that generate 66% of total revenue, and dependence on a partnership model that can pressure growth if key relationships change. Although 1Q:26 showed operating expenses declined by about 5% year over year on a percent of revenue basis and net revenue retention was 128%, the company still faces profitability, cybersecurity, and execution risks that could limit sustainable scale.